Merck (MRK) Misses Q4 EPS by 6c, FY Guidance Tops Views
Tweet
Share
E-mail
Get Alerts MRK Hot Sheet
Price: $152.55 +2.39%
Financial Fact:
Total Costs, Expenses and Other: 12.82B
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Total Costs, Expenses and Other: 12.82B
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Merck (NYSE: MRK) reported Q4 EPS of $1.32, $0.06 worse than the analyst estimate of $1.38. Revenue for the quarter came in at $12.5 billion versus the consensus estimate of $12.68 billion.
GUIDANCE:
Merck sees FY2021 EPS of $6.48-$6.68, versus the consensus of $6.41. Merck sees FY2021 revenue of $51.8-53.8 billion, versus the consensus of $51.77 billion.
For earnings history and earnings-related data on Merck (MRK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Morgan Stanley Upgrades Merck (MRK) to Overweight
- UBS Downgrades Merck (MRK) to Neutral
- RBC Capital Downgrades Merck (MRK) to Sector Perform
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Earnings, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
